Evidence map›Paper›PMID 39931058›Full record

ArticleFrontiers in immunology2025

Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin.

Itai Falicovich, Boaz Nachmias, Shlomo Elias, Eran Zimran, Adir Shaulov, Polina Stepensky, Batia Avni, Sigal Grisariu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Itai FalicovichFaculty of Medicine, The Hebrew University, Jerusalem, Israel.
Boaz NachmiasDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Shlomo EliasBone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Eran ZimranBone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Adir ShaulovDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Polina StepenskyBone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Batia AvniBone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Sigal GrisariuBone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anti-Thymocyte Globulin (ATG) is commonly used to prevent graft-versus-host disease (GVHD), but the optimal dosage and type of ATG remains to be determined. Objective: We compared retrospectively the safety and efficacy outcomes of allogeneic transplantation using low-dose ATG-Fresenius (15mg/kg) and ATG-Thymoglobulin (10mg/kg) for GVHD prevention. Study design: Ninety-eight patients were included, with 46 in the ATG-T group and 52 in the ATG-F group. The median age was 48 years in the ATG-T group (range 20-71) and 50 years in the ATG-F group (range 18-73). Baseline characteristics were similar, with slightly more HLA mismatched donors and single-agent cyclosporine GVHD prophylaxis use in the ATG-T group. Additionally, the ATG-F group had more myeloid leukemia and myelodysplastic syndrome patients, while the ATG-T group had more lymphoma patients. Results: The cumulative incidence of acute GVHD (aGVHD) grade II-IV and chronic GVHD (cGVHD) showed no significant differences. Multivariate analysis indicated that donor HLA mismatch influenced aGVHD risk significantly (p=0.005), and myeloablative conditioning increased cGVHD risk. Bacteremia and CMV reactivation rates were similar, but EBV DNA viremia was higher in the ATG-T group (22% Conclusions: This study highlights the safety and efficacy of low-dose ATG-F compared to a relatively high dose ATG-T. Prospective studies are necessary to validate the safety and efficacy of low dose ATG-F for GVHD prevention.

Indexed as

Antilymphocyte SerumGraft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunosuppressive AgentsAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTransplantation ConditioningTransplantation, HomologousTreatment OutcomeYoung AdultAntilymphocyte SerumImmunosuppressive Agentsthymoglobulinacute GVHDallogenic bone marrow transplantationATG FreseniusATG thymoglobulinchronic GVHD

Identifiers

PMID39931058
PMCPMC11807999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.